Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Basit Öğe Kaydı
dc.authoridYildirim, Hasan cagri/0000-0003-3060-377X
dc.authoridBayram, Ertugrul/0000-0001-8713-7613
dc.authoridmajidova, nargiz/0000-0002-2575-5819
dc.authoriduzun, mehmet/0000-0002-8596-4233
dc.authoridozturk, banu/0000-0003-0290-8787
dc.contributor.authorYildirim, Hasan Cagri
dc.contributor.authorBayram, Ertugrul
dc.contributor.authorChalabiyev, Elvin
dc.contributor.authorMajidova, Nargiz
dc.contributor.authorAvci, Tugay
dc.contributor.authorGuzel, Halil Goksel
dc.contributor.authorKapar, Caner
dc.date.accessioned2025-02-22T14:08:56Z
dc.date.available2025-02-22T14:08:56Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractNon-clear cell renal cell carcinoma (non-ccRCC) is a highly heterogeneous disease group, accounting for approximately 25% of all RCC cases. Due to its rarity and especially heterogeneity, phase III trial data is limited and treatment options generally follow those of clear cell RCC. In the literature, there exists a number of studies with sunitinib, cabozantinib, and everolimus, but data on the efficacy of pazopanib are limited. Our aim in this study was to compare the efficacy of pazopanib and sunitinib, in a multicenter retrospective cohort of non-ccRCC patients. Our study included patients diagnosed with non-ccRCC who received pazopanib or sunitinib treatment as first-line therapy from 22 tertiary hospitals. We compared the progression-free survival (PFS), overall survival (OS), and response rates of pazopanib and sunitinib treatments. Additionally, we investigated prognostic factors in non-ccRCC. PFS and response rates of sunitinib and pazopanib were found to be similar, while a numerical difference was observed in OS. Being 65 years and older, being in the intermediate or poor risk group according to the International Metastatic Renal Cell Carcinoma Database Consortium, having liver metastases, presence of a sarcomatoid component, and having de novo metastatic disease were found to be significantly associated with shorter PFS. Pazopanib treatment appears to have similar efficacy in the treatment of non-ccRCC compared to sunitinib. Though randomized controlled trials are lacking and will probably be never be available, we suggest that pazopanib could be a preferred agent like sunitinib and cabozantinib. Pazopanib and sunitinib treatments show similar progression free survival, overall survival and objective response rate.IMDC risk group, liver metastasis, sarcomatoid component and de novo metastatic disease were determined as prognostic factorsen_US
dc.identifier.doi10.1080/1120009X.2024.2403051
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.pmid39257075en_US
dc.identifier.scopus2-s2.0-85203493425en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1080/1120009X.2024.2403051
dc.identifier.urihttps://hdl.handle.net/11468/29718
dc.identifier.wosWOS:001309938500001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal of Chemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectNon-clear cell renal cell carcinomaen_US
dc.subjectsunitiniben_US
dc.subjectpazopaniben_US
dc.subjectTKIsen_US
dc.subjectrare tumorsen_US
dc.subjectpapillary RCCen_US
dc.titleComparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu